Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pilot study of PHA-739358 in relapsed chronic myeloid leukemia after imatinib or c-ABL therapy
2006-006881-40Phase 2Terminated
- Sponsor
- Nerviano Medical Sciences
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of danusertib in chronic myelogenous leukemia (CML), sponsored by Nerviano Medical Sciences. Primary endpoints: Antileukemic response and Cytogenetic response. Started Mar 2007; status: terminated.
02
Drugs
danusertib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2006-006881-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006881-40.